Literature DB >> 15578920

Targeting the STAT pathway in head and neck cancer: recent advances and future prospects.

N G Nikitakis1, H Siavash, J J Sauk.   

Abstract

Head and neck cancer, the sixth most common type of cancer worldwide, is associated with a dismal prognosis that has minimally improved during the last few decades. Future advances in the treatment and prognosis of this fatal disease largely rely upon a better understanding of the molecular events that underlie tumor development and progression, allowing specific targeting of the involved molecules and pathways. In this context, recent efforts have revolved around a family of transcription factors known as STATs (signal transducers and activators of transcription). STAT proteins comprise a family of latent cytoplasmic transcription factors that become transiently activated in response to extracellular signals, leading to regulation of diverse physiological responses. There is compelling evidence that persistent activation of specific STAT molecules, especially Stat3 and Stat5, possesses oncogenic properties in a number of human cancers, including head and neck cancer. The presence of constitutively activated STAT molecules in cancer cells is mainly attributed to the dysregulation of upstream activating pathways and the aberration of negative regulatory mechanisms. The end result is induction of specific target genes that stimulate cell proliferation, prevent apoptosis, promote angiogenesis and facilitate tumor immune evasion. Therefore, targeting and disruption of oncogenic STAT signaling may theoretically be accomplished through various approaches, involving direct (e.g. interference with the various facets of STAT expression, activation or function) and indirect strategies (e.g. inhibition of upstream signaling events and enhancement or restoration of negative regulatory mechanisms). The availability of multiple potential targets for interruption of aberrant STAT signaling in cancer and the thus-far promising results have generated optimism for the clinical applicability of STAT targeting in head and neck cancer, which is the focus of this review.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15578920     DOI: 10.2174/1568009043332736

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  18 in total

Review 1.  The biological functions of the versatile transcription factors STAT3 and STAT5 and new strategies for their targeted inhibition.

Authors:  Sylvane Desrivières; Christian Kunz; Itamar Barash; Vida Vafaizadeh; Corina Borghouts; Bernd Groner
Journal:  J Mammary Gland Biol Neoplasia       Date:  2006-01       Impact factor: 2.673

2.  Small interfering RNA survivin and GRIM-19 co-expression salmonella plasmid inhibited the growth of laryngeal cancer cells in vitro and in vivo.

Authors:  Lian-Ji Wen; Li-Fang Gao; Chun-Shun Jin; He-Jia Zhang; Kun Ji; Jing-Pu Yang; Xue-Jian Zhao; Ming-Ji Wen; Guo-Fang Guan
Journal:  Int J Clin Exp Pathol       Date:  2013-09-15

3.  Ultraviolet radiation and 12-O-tetradecanoylphorbol-13-acetate-induced interaction of mouse epidermal protein kinase Cε with Stat3 involve integration with ERK1/2.

Authors:  Jordan Marshall Sand; Bilal Bin Hafeez; Moammir Hasan Aziz; Emily Marie Siebers; Nancy Ellen Dreckschmidt; Ajit Kumar Verma
Journal:  Mol Carcinog       Date:  2011-04-07       Impact factor: 4.784

Review 4.  Signal transducer and activator of transcription 5a/b: biomarker and therapeutic target in prostate and breast cancer.

Authors:  Mateusz Koptyra; Shilpa Gupta; Pooja Talati; Marja T Nevalainen
Journal:  Int J Biochem Cell Biol       Date:  2011-06-17       Impact factor: 5.085

5.  Targeting transcription factor Stat5a/b as a therapeutic strategy for prostate cancer.

Authors:  Zhiyong Liao; Marja T Nevalainen
Journal:  Am J Transl Res       Date:  2010-11-21       Impact factor: 4.060

6.  Sulindac induces apoptosis and inhibits tumor growth in vivo in head and neck squamous cell carcinoma.

Authors:  Mark A Scheper; Nikolaos G Nikitakis; Risa Chaisuparat; Silvia Montaner; John J Sauk
Journal:  Neoplasia       Date:  2007-03       Impact factor: 5.715

7.  Protein kinase Cvarepsilon mediates Stat3Ser727 phosphorylation, Stat3-regulated gene expression, and cell invasion in various human cancer cell lines through integration with MAPK cascade (RAF-1, MEK1/2, and ERK1/2).

Authors:  M H Aziz; B B Hafeez; J M Sand; D B Pierce; S W Aziz; N E Dreckschmidt; A K Verma
Journal:  Oncogene       Date:  2010-03-15       Impact factor: 9.867

8.  Immunohistochemical expression of the oncogenic molecules active Stat3 and survivin in benign and malignant salivary gland tumors.

Authors:  Nikolaos G Nikitakis; Mark A Scheper; Vasileios S Papanikolaou; Alexandra Sklavounou; John J Sauk
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2009-03-09

9.  VIP inhibits human HepG2 cell proliferation in vitro.

Authors:  Afaf Absood; Bin Hu; Nermine Bassily; Lisa Colletti
Journal:  Regul Pept       Date:  2007-11-21

10.  Cross talk initiated by endothelial cells enhances migration and inhibits anoikis of squamous cell carcinoma cells through STAT3/Akt/ERK signaling.

Authors:  Kathleen G Neiva; Zhaocheng Zhang; Marta Miyazawa; Kristy A Warner; Elisabeta Karl; Jacques E Nör
Journal:  Neoplasia       Date:  2009-06       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.